TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06626113

Intervention type: DRUG
Intervention: ascorbic acid
Description: ascorbic acid
Study: NCT06624553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre 2, flash glucose monitoring
Description: Currently, at the Hospital de la Santa Creu i Sant Pau, when starting monitoring in people with DM2, capillary glycemia monitoring is used, following the therapeutic education protocols in basal insulinization in the debut of DM2 and in optimization of treatment, protocols that are also applied to similar cases.~The intervention group (FreeStyle Libre 2) will be provided with the necessary material to carry out the monitoring via a glucose sensor. Satisfaction with treatment will be assessed at the final study visit.
Study: NCT06624761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: A randomized study investigating ShotBlocker in painkillers containing different active ingredients could not be found.
Study: NCT05718687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT021601
Description: Single oral dose of 200 mg GBT021601, containing \~74 kBq (\~2 µCi) of \[14C\]-GBT021601
Study: NCT06413355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]-FAPI-74
Description: A positron-emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo expression of FAP with positron emission tomography (PET/CT).
Study: NCT06759779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: Inspiratory muscle training will be performed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: expiratory muscle training
Description: Expiratory muscle training will be performed
Study: NCT06763796

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postural Decryption Technique
Description: Assessment:~PDT begins with visual inspection and palpation to check postural alignment and identify joint or muscle imbalances. Evaluations proceed distal to proximal, examining the spine and shoulder complex in coronal, sagittal, and transverse planes to assess symmetry and neutral positioning.~Treatment Process:~PDT applies the 4R Technique:~1. Reposition - Correct joint alignment.~2. Restore - Release muscle tension and adhesions.~3. Reinforce - Strengthen stabilizing muscles.~4. Retrain - Improve movement patterns and posture.~Key Techniques:~1. Spinal and Shoulder Adjustments: Manual traction, mobilizations, and stretches.~2. Joint Mobilization: Multi-directional gliding within pain-free ranges.~3. Trigger Point Therapy: 5-10 seconds of pressure to relieve localized pain.~4. Proprioception Training: Balance challenges to improve stability and control.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chinese Medicine (TCM) Massage Therapy
Description: Definition:~A manual therapy based on Traditional Chinese Medicine (TCM) principles, using techniques like kneading, pressing, rolling, and stretching to relieve pain, improve circulation, and enhance mobility.~Key Features:~1. Techniques: Soft tissue manipulation, joint mobilization, and acupressure.~2. Focus: Pain relief, joint function recovery, and muscle relaxation.~Treatment Plan:~4 weeks, 5 sessions per week, 40 minutes per session.
Study: NCT06763809

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PMS Capsule
Description: Participants will take 2 capsules, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Capsule Placebo
Description: Participants will take 2 capsules, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PMS Gummy
Description: Participants will take 2 gummies, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gummy Placebo
Description: Participants will take 2 gummies, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
Study: NCT06763744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P2Y12 antagonist monotherapy
Description: CYP2C19 genetic testing is performed before discharge after stent insertion. Depending on the test results, rapid (CYP2C19\*1/\*17 or \*17/\*17) or normal (CYP2C19\*1/\*1) metabolizers are treated with clopidogrel monotherapy, and intermediate or poor metabolizers (with CYP2C19\*2 or \*3 alleles) are treated with potent P2Y12 inhibitors (prasugrel or ticagrelor) monotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel + aspirin
Description: In this group, a potent P2Y12 inhibitor was changed to clopidogrel (un-guided) 1 month after PCI with maintenance of co-prescription of aspirin (DAPT).
Study: NCT06764433

Intervention type: PROCEDURE
Group type: OTHER
Intervention: GONPRF
Description: GON PRF treatment, which we apply by imaging the target nerve and surrounding structures with the proximal technique (at C2 level) under USG guidance in patients who do not respond to conservative treatments for cervicogenic headache.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Proximal GONPRF
Description: Ultrasound-guided pulsed radiofrequency treatment of the greater occipital nerve at the C2 level
Study: NCT06764654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental implant placement
Description: Placement of two dental implants in the jaw.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant placement
Description: Placement of two dental implants in the jaw.
Study: NCT04594642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0486 IV
Description: AZD0486 is a bispecific antibody targeting CD19 on tumor cells and CD3 on T-cells leading to T cell-mediated cytotoxicity of malignant B cells
Study: NCT06009601

Intervention type: DIAGNOSTIC_TEST
Intervention: Pectus Study Form
Description: Pectus study forms consisting of clinical and radiological measurements of patients aged 3-18 years who applied to the outpatient clinic with chest deformity will be filled in in detail.~In addition, this study form includes 'Quality of Life Evaluation Form in Pectus Deformity', 'Social Comparison Scale', 'Sleep Disorder Scale for Children', 'Anxiety Disorders Screening Scale in Children', 'Pediatric Quality of Life Questionnaire' designed for patients and their relatives. PedsQL)', 'SRS-22 Patient Questionnaire', 'Beck Anxiety Scale' and 'Informed Consent Form' designed for patients and their relatives.

Intervention type: DIAGNOSTIC_TEST
Intervention: Adams Test
Description: Adams test (forward bending test) (+) was measured by Bunnell scoliometer (scoliosis assessment tool) and ATR (angle of trunk rotation angle) values were 7 degrees in patients who meet the inclusion criteria will be included in the study by filling out an informed consent form

Intervention type: DIAGNOSTIC_TEST
Intervention: Scoliosis Graphy
Description: ATR (angle of trunk rotation) values above 7 degrees on bunnell scoliometer were determined. Afterwards, patients who meet the inclusion criteria will be included in the study by filling out an informed consent form and a scoliosis graphy will be requested.~Coronal, sagittal balance; coronal and sagittal cobb angles will be measured from posterior-anterior (PA) (posterior-anterior) and lateral (lateral) scoliosis radiographs.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function test
Description: Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders.~There are 2 types of disorders that cause problems with air moving in and out of the lungs:~Obstructive. This is when air has trouble flowing out of the lungs due to airway resistance. This causes a decreased flow of air.~Restrictive. This is when the lung tissue and/or chest muscles can't expand enough. This creates problems with air flow, mostly due to lower lung volumes.
Study: NCT05115344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 25mg
Description: 1 case,The starting dose,Take the medicine once on D1,D 5-21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 50mg
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 100mg
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 150mg
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 225mg
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 325mg
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.
Study: NCT04934722

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Androgen Deprivation Therapy (ADT)
Description: Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
Study: NCT06207799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Given by SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given by SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given by IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Description: Given by IV
Study: NCT05593757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Description: Oral quinidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Description: Oral quinidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Oral verapamil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Oral verapamil
Study: NCT05054309

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bifidobacterium longum
Description: A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium longum
Description: A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome
Study: NCT04882098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive guselkumab as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive guselkumab as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive guselkumab as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as SC injection.
Study: NCT04945330

Intervention type: DRUG
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: Follow clinical practice

Intervention type: DRUG
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: Follow clinical practice

Intervention type: DRUG
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: Follow clinical practice

Intervention type: DRUG
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: Follow clinical practice

Intervention type: DRUG
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: Follow clinical practice

Intervention type: DRUG
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: Follow clinical practice

Intervention type: DRUG
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: Follow clinical practice

Intervention type: DRUG
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: Follow clinical practice
Study: NCT06470074

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial electrical stimulation
Description: Transcranial electrical stimulation can modulate the brain functional network through weak transcranial current

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial electrical stimulation
Description: Transcranial electrical stimulation can modulate the brain functional network through weak transcranial current
Study: NCT06247202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Phone Education (mhealth)
Description: Nutrition and Health Education module delivered through m-health approach (smart phones)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper Education (conventional)
Description: Nutrition and Health Education module delivered through conventional approach (paper)
Study: NCT06147518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin: 1.5g/d CTPA,1g/d CTPB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin: 1.5g/d CTPA,1g/d CTPB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin: Assess HbA1c/HBSG at 8 weeks, increase sitagliptin to 100 mg if HbA1c\>7%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Assess HbA1c/HBSG at 8 weeks, increase Dapagliflozin to 10 mg if HbA1c\>7%
Study: NCT06434714

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auricular percutaneous nerve field stimulator
Description: Percutaneous nerve field stimulator device placed on the ear for 5 days

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham auricular percutaneous nerve field stimulator
Description: Non-functioning percutaneous nerve field stimulator device placed on the ear for 5 days
Study: NCT04737109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: ADT per institutional standards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: ADT per institutional standards
Study: NCT05782010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PexyEazy
Description: PexyEazy procedure on patients with hemorrhoidal disease grade II and III. The study is descriptive and non-comparable to evaluate the safety and performance of PexyEazy.
Study: NCT05753384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment of TKI in CML
Description: continued treatment with TKI at randomization a then stopped treatment 12 months after randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment of TKI in CML
Description: continued treatment with TKI at randomization a then stopped treatment 12 months after randomization
Study: NCT05481385

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference preparation-Reference preparation-Test Preparation
Description: Under fed conditions, subjects randomly divided into RRT group were given one tablet of reference preparation first, and then one tablet of reference preparation after cleaning period, and then one tablet of test preparation after cleaning period.
Study: NCT04935775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untrained Touch
Description: Subject's feet, ankles, and lower legs are touched and rubbed during a bone marrow biopsy procedure.
Study: NCT05481385

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference preparation-Test Preparation-Reference preparation
Description: Under fed conditions, subjects randomly divided into RTR group were given one tablet of reference preparation first, and then one tablet of test preparation after cleaning period, and then one tablet of reference preparation after cleaning period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test Preparation-Reference preparation-Reference preparation
Description: Under fed conditions, subjects randomly divided into RTR group were given one tablet of test preparation first, and then one tablet of reference preparation after cleaning period, and then one tablet of reference preparation after cleaning period.
Study: NCT06530680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: Two 1-hour sessions of hippotherapy for eight weeks.
Study: NCT06175585

Intervention type: OTHER
Intervention: narrative nursing
Description: The narrative nursing process is based on the practice of two-line system proposed by Jiang, which is carried out in a separate classroom, office or ward with sufficient space and good lighting. The environment is set to the right temperature and humidity for comfortable face-to-face conversation. This process is done in stages, depending on how often the patient is dialysis three or more times a week.~Each session lasts about 30 minutes and the whole process lasts four weeks. Adjust to the specific needs of each patient .
Study: NCT03770299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days
Study: NCT05712629

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread and vla dadiah
Description: Consumption bread and vla dadiah to pregnant women 1 Pieces a day during 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bread and vla without dadiah
Description: Consumption bread and vla without dadiah to pregnant women 1 Pieces a day during 12 weeks.
Study: NCT06180369

Intervention type: OTHER
Group type: OTHER
Intervention: GC Fuji Triage ® GC America Inc., Alsip, Illinois )
Description: Fissur Sealent application
Study: NCT03770299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Observation by the investigator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Observation by the investigator
Study: NCT06162806

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided caudal epidural block using 1ml/kg of Bupivacaine 0.25% + 0.5microgram/kg of Fentanyl
Description: injection of local anesthetic mixture(Bupivacaine +Fentanyl ) in the caudal epidural space under guidance of ultrasound, it is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided caudal epidural block using 50 mg of Magnesium sulfate added to(1ml/kg of Bupivacaine 0.25% + 0.5microgram/kg of Fentanyl)
Description: injection of local anesthetic mixture(Bupivacaine +Fentanyl +magnesium sulfate) in the caudal epidural space under guidance of ultrasound, it is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space
Study: NCT05177770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRF617
Description: SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
Study: NCT05261347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mulligan mobilisation
Description: an active mobilisation with movement on elbow according to mulligan's protocol

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: a lateral glide